Perception of risk: the state of COX-2 selective inhibitors.

被引：2

作者：

Simon L.S. ^{[1
]}

Strand V. ^{[1
]}

机构：

[1] Harvard Medical School, Beth Israel Deaconess Medical Center, Suite 5A, 110 Francis Street, Boston, 02115, MA

来源：

Current Rheumatology Reports | 2005年 / 7卷 / 3期

关键词：

Celecoxib; Naproxen; Rofecoxib; Etoricoxib; Valdecoxib;

D O I：

10.1007/s11926-996-0032-4

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

页码：163 / 166

页数：3

共 50 条

[41] Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core [J].

Sarnpitak, Pakornwit ;

Mujumdar, Prashant ;

Morisseau, Christophe ;

Hwang, Sung Hee ;

Hammock, Bruce ;

Iurchenko, Vladimir ;

Zozulya, Sergey ;

Gavalas, Antonis ;

Geronikaki, Athina ;

Ivanenkov, Yan ;

Krasavin, Mikhail .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 84 :160-172

[42] Defining COX-2 inhibitors [J].

Lipsky, PE .

JOURNAL OF RHEUMATOLOGY, 2000, 27 :13-16

[43] Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation [J].

Pinheiro, RM ;

Calixto, JB .

INFLAMMATION RESEARCH, 2002, 51 (12) :603-610

[44] Blood pressure effects of COX-2 inhibitors [J].

Krum, Henry ;

Aw, Tai-Juan ;

Liew, Danny ;

Haas, Steven .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2006, 47 :S43-S48

[45] The Role of COX-2 Inhibitors in Pain Modulation [J].

Frederic Camu ;

Lin Shi ;

Caroline Vanlersberghe .

Drugs, 2003, 63 :1-7

[46] COX-2 Inhibitors for the management of postoperative pain [J].

Schug, Stephan A. .

ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2010, 45 (01) :56-60

[47] Disconnect between COX-2 selective inhibition and cardiovascular risk in preclinical models [J].

Koshman, Yevgeniya E. ;

Bielinski, Aimee L. ;

Bird, Brandan M. ;

Green, Jonathon R. ;

Kowalkowski, Kenneth L. ;

Lai-Zhang, Jie ;

Mahalingaiah, Prathap Kumar ;

Sawicki, James W. ;

Talaty, Nari N. ;

Wilsey, Amanda S. ;

Zafiratos, Mark T. ;

Van Vleet, Terry R. .

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2023, 120

[48] COX-2, NSAIDs, and cardiovascular risk [J].

McGettigan P. ;

Henry D. .

Current Cardiovascular Risk Reports, 2007, 1 (4) :296-302

[49] Pyridazine derivatives as selective COX-2 inhibitors: A review on recent updates [J].

Ewieda, Sara Y. ;

Ahmed, Eman M. ;

Hassan, Rasha A. ;

Hassan, Marwa S. A. .

DRUG DEVELOPMENT RESEARCH, 2023, 84 (08) :1595-1623

[50] Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease [J].

Aisen, PS .

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 23 (04) :S35-S40

← 1 2 3 4 5 →